New York, New York–(Newsfile Corp. – January 4, 2025) – WHY: The Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. the important thing February 10, 2025 leads the plaintiff’s deadline.

WHATEVER: If you purchased Cassava securities during the Class Period you may be entitled to compensation free of any out-of-pocket fees or expenses through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for class action information. A class action lawsuit has been filed. If you want to serve as the lead plaintiff, you must move the Court no later than February 10, 2025. The lead plaintiff is a representative party acting on behalf of other class members in the conduct of litigation.

WHY ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, the companies issuing the notices do not have the same experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen who refer clients or partners to the law firms that actually litigate the cases. Be wise in choosing advice. The Rosen Law Firm represents investors worldwide, concentrating its practice in securities class actions and shareholder derivative litigation. The Rosen Law Firm achieved the largest securities class action settlement against a Chinese Company at that time. The Rosen Law Firm is ranked No. 1 in the ISS Securities Class action (WA:) Services for the number of securities class action settlements in 2017. The company has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the company earned over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, the defendants throughout the Class Period created the false impression that they had reliable information about Cassava’s drug prospects and expected growth while minimizing the risk from a potential drug failure. However, in fact, the repeated statements of Cassava’s dependence on simufilam, the leading candidate of Cassava’s drug, and reliance on spinning statistically insignificant data from the Phase 2 study fell into reality on the potential of simufilm; Cassava has no drug that can prevent the development of Alzheimer’s Disease, even when trying to treat only mild and moderate cases. When the true details entered the market, the lawsuit claims that investors suffered damage.

To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for class action information.

No Class Verified. Until a class is certified, you will not be represented by counsel unless you hold one. You can choose the advice you want. You can also stay out of class and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent on serving as the lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https :// /www.facebook.com/rosenlawfirm.

Attorney Advertising. The first results do not guarantee a similar result.

—————————-

Contact information:

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/236062